Active	Status	Sponsor type	Region	Phase	Filter
8 Active 3 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Molina, María
RXC007 0002, NCT05570058 / 2022-000498-15: Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis Jan 2024 - Mar 2024 : Q1'24 - Topline data from trial for IPF	Active, not recruiting	2	48	Europe, RoW	RXC007, Placebo	Redx Pharma Plc, Simbec-Orion Group	IPF, Fibrosis	06/24	01/25
NCT06317285: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)	Recruiting	2	150	Europe, Canada, US, RoW	GSK3915393, Placebo	GlaxoSmithKline	Idiopathic Pulmonary Fibrosis	03/26	03/26
Molina, Maria Molina
Neptuno, NCT04784559 / 2020-005951-19: Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection	Terminated	3	205	Europe, RoW	Plitidepsin, Dexamethasone, Remdesivir, Favipiravir	PharmaMar	COVID-19 Infection	03/23	03/23
IMPALA-2, NCT04544293 / 2020-001263-85: Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	Active, not recruiting	3	160	Europe, Canada, Japan, US, RoW	Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), Placebo	Savara Inc., Savara ApS,	Autoimmune Pulmonary Alveolar Proteinosis	11/23	11/24
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis	Active, not recruiting	3	597	Europe, RoW	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease	07/25	07/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
RXC007 0002, NCT05570058 / 2022-000498-15: Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis Jan 2024 - Mar 2024 : Q1'24 - Topline data from trial for IPF	Active, not recruiting	2	48	Europe, RoW	RXC007, Placebo	Redx Pharma Plc, Simbec-Orion Group	IPF, Fibrosis	06/24	01/25
NCT05032066: A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis	Terminated	2	153	Europe, Canada, Japan, US, RoW	HZN-825, Placebo	Amgen	Idiopathic Pulmonary Fibrosis	07/24	01/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Molina, María
RXC007 0002, NCT05570058 / 2022-000498-15: Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis Jan 2024 - Mar 2024 : Q1'24 - Topline data from trial for IPF	Active, not recruiting	2	48	Europe, RoW	RXC007, Placebo	Redx Pharma Plc, Simbec-Orion Group	IPF, Fibrosis	06/24	01/25
NCT06317285: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)	Recruiting	2	150	Europe, Canada, US, RoW	GSK3915393, Placebo	GlaxoSmithKline	Idiopathic Pulmonary Fibrosis	03/26	03/26
Molina, Maria Molina
Neptuno, NCT04784559 / 2020-005951-19: Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection	Terminated	3	205	Europe, RoW	Plitidepsin, Dexamethasone, Remdesivir, Favipiravir	PharmaMar	COVID-19 Infection	03/23	03/23
IMPALA-2, NCT04544293 / 2020-001263-85: Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	Active, not recruiting	3	160	Europe, Canada, Japan, US, RoW	Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), Placebo	Savara Inc., Savara ApS,	Autoimmune Pulmonary Alveolar Proteinosis	11/23	11/24
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis	Active, not recruiting	3	597	Europe, RoW	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease	07/25	07/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
RXC007 0002, NCT05570058 / 2022-000498-15: Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis Jan 2024 - Mar 2024 : Q1'24 - Topline data from trial for IPF	Active, not recruiting	2	48	Europe, RoW	RXC007, Placebo	Redx Pharma Plc, Simbec-Orion Group	IPF, Fibrosis	06/24	01/25
NCT05032066: A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis	Terminated	2	153	Europe, Canada, Japan, US, RoW	HZN-825, Placebo	Amgen	Idiopathic Pulmonary Fibrosis	07/24	01/25